NVS

BASEL, SWITZERLAND June 23, 2021 /3BL Media/ -— Novartis and Hewlett Packard Enterprise (HPE) today announced a collaboration that aims to accelerate the use of data and digital technologies within...

Novartis AG (NYSE: NVS) announced new data from the completed two-copy cohort of Phase 3 SPR1NT trial of Zolgensma (onasemnogene abeparvovec), gene therapy for spinal muscular atrophy (SMA). The data were presented at the European Academy for Neurology Virtual Congress 2021. In the open-label study, investigators tested the gene therapy in a total of 29 patients six weeks or younger who had a genetic diagnosis of SMA plus two or three copies of the protein-coding gene SMN2 but had not yet develo

All children (100%) treated presymptomatically in the SPR1NT two-copy cohort survived without respiratory or nutritional support, and sat independently for ≥30 seconds, most (11/14) within the WHO window of expected normal development The majority of children (82%) treated in STR1VE-EU achieved developmental motor milestones not observed in the natural history of SMA Type 1, including patients with more severe disease More than 1,200 patients have now been treated with Zolgensma globally across

Shares in CureVac fell by almost half in premarket trading, pointing to hefty losses for investors when the market reopens, after the company reported disappointing results from a study of its experimental Covid-19 vaccine.

In this episode of Influencers, Eli Lilly Chairman & CEO David Ricks joins Andy to discuss the latest in the pharmaceutical industry, new progress in the fight against COVID-19, and potential groundbreaking advancements for the treatment of Alzheimer’s.

Eli Lilly CEO David Ricks joins 'Influencers with Andy Serwer' to discuss progress in the fight against COVID-19.

Eli Lilly CEO David Ricks joins 'Influencers with Andy Serwer' to discuss the FDA's approval of Biogen's new Alzheimer’s drug.

In this article, we discuss the 10 best biotech penny stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Biotech Penny Stocks to Buy Now. The scintillating pace of technological advancement in the world over the past few decades has transformed the fortunes […]

FDA approves Novo Nordisk's (NVO) obesity treatment, Wegovy and Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine, Prevnar 20.

First-in-class, oral, targeted factor B inhibitor iptacopan substantially reduced both intra- and extravascular hemolysis when given as monotherapy in a Phase II study of anti-C5 naïve paroxysmal nocturnal hemoglobinuria (PNH) patients1New results are promising for potential use of iptacopan as monotherapy in PNH, a rare and life-threatening blood disorder2,3; results from a previous Phase II study showed iptacopan substantially improved hematological response as add-on to standard-of-care (ecul

Novartis plans to close a plant in the southern Swiss town of Locarno, the drugmaker said on Wednesday, citing falling demand for testing products. Around 50 jobs are set to go by shuttering the facility in stages by the end of 2023, it added in a statement. The Pharmanalytica testing facility in Locarno specialises in performing stability tests and specific release tests for Novartis products.

Novartis' (NVS) rare kidney disease candidate meets its primary goal in a phase II study.

Novartis AG (NYSE: NVS) announced data from Phase 2 trial evaluating iptacopan (LNP023) in rare kidney disease IgA nephropathy (IgAN). Data were presented at the 58th ERA-EDTA Congress. IgA nephropathy, also known as Berger's disease, occurs when an antibody called immunoglobulin A (IgA) builds up in kidneys, resulting in local inflammation that, over time, can hamper kidneys' ability to filter waste. The trial met its primary endpoint data showing the targeted factor B inhibitor reduced protein

Phase II primary endpoint results for investigational iptacopan in IgAN demonstrated effective and clinically meaningful reduction of proteinuria1 – a key risk predictor in kidney disease progression2Iptacopan also showed a trend toward stabilization of kidney function1; Phase III clinical trial APPLAUSE is underwayThere are no currently approved treatments for IgAN – a rare and often progressive kidney disease that mainly affects young adults and can progress to kidney failure3-7Iptacopan is in

Novartis AG (NYSE: NVS) reported the final analysis from the NETTER-1 phase 3 study comparing Lutathera plus 30 mg Sandostatin LAR (octreotide) to 60 mg octreotide LAR in patients with midgut neuroendocrine tumors. Lutathera failed to significantly prolong the lives of patients with midgut neuroendocrine tumors, according to data unveiled at the American Society of Clinical Oncology. When used alongside Novartis’ Sandostatin LAR in the trial, Lutathera reduced the risk of death by 16% compared w

Novartis (NVS) posts results from a late-stage study on radioligand therapy at the 2021 ASCO.

Tabrecta® (capmatinib) showed a median overall survival (OS) of 20.8 months in treatment-naïve patients and 13.6 months in previously-treated patients in first published mature data1,2 Tabrecta achieved 65.6% overall response rate (ORR) in first-line and 51.6% in second-line settings in new expansion cohort analysis of additional patients1,2 Patient-reported outcomes on quality-of-life symptoms were also presented3 Tabrecta is the first therapy approved by the FDA to specifically target metastat

Tislelizumab demonstrated a 30% reduction in the risk of death and extended median overall survival by 2.3 months compared to chemotherapy in advanced or metastatic esophageal squamous cell carcinoma after prior systemic therapy1 Additional Phase II data presented at ASCO showed tislelizumab demonstrated durable anti-tumor activity in patients with microsatellite instability-high, or mismatch-repair-deficient, solid tumors2 Basel, June 4, 2021 — Novartis announced today results from the pivotal

MESO earnings call for the period ending March 31, 2021.

At final analysis, study showed clinically relevant improvement in median overall survival with a difference of 11.7 months between arms (Hazard ratio (HR): 0.84 with 95% CI: (0.60, 1.17) (p=0.30, two-sided))1 No new safety signals emerged in long-term follow-up with median of 6.3 years; safety profile consistent with previously reported results1 Previously reported primary analysis demonstrated statistically significant improvement in progression free survival2 Novartis is committed to reimagin